Tumor Microenvironment Reprogramming Improves Nanomedicine-Based Chemo-Immunotherapy in Sarcomas

Sarcomas are a heterogeneous group of rare cancers that originate in soft tissues or bones. Their complexity and tendency for metastases make treatment challenging, highlighting the need for new therapeutic approaches to improve patient survival. The difficulties in treating these cancers primarily...

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer therapeutics Vol. 23; no. 11; pp. 1555 - 1567
Main Authors Charalambous, Antonia, Mpekris, Fotios, Panagi, Myrofora, Voutouri, Chrysovalantis, Michael, Christina, Gabizon, Alberto A, Stylianopoulos, Triantafyllos
Format Journal Article
LanguageEnglish
Published United States 04.11.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Sarcomas are a heterogeneous group of rare cancers that originate in soft tissues or bones. Their complexity and tendency for metastases make treatment challenging, highlighting the need for new therapeutic approaches to improve patient survival. The difficulties in treating these cancers primarily stem from abnormalities within the tumor microenvironment (TME), which leads to reduced blood flow and oxygen levels in tumors. Consequently, this hampers the effective delivery of drugs to tumors and diminishes treatment efficacy despite higher toxic doses of chemotherapy. In this study, we tested the mechanotherapeutic ketotifen combined with either pegylated liposomal doxorubicin (PLD) or pegylated liposomal coencapsulated alendronate-doxorubicin (PLAD) plus anti-programmed cell death protein 1 antibody in mouse models of fibrosarcoma and osteosarcoma. We found that ketotifen successfully reprogrammed the TME by reducing tumor stiffness and increasing perfusion, proven by changes measured by shear-wave elastography and contrast-enhanced ultrasound, respectively, and enhanced the therapeutic efficacy of our nanomedicine-based chemo-immunotherapy protocols. Furthermore, we observed a trend toward improved antitumor responses when nano-chemotherapy is given alongside anti-programmed cell death protein 1 and when the immunomodulator alendronate was present in the treatment. We next investigated the mechanisms of action of this combination. Ketotifen combined with nanomedicine-based chemo-immunotherapy increased T-cell infiltration, specifically cytotoxic CD8+ T cells and CD4+ T helper cells, and decreased the number of regulatory T cells. In addition, the combination also altered the polarization of tumor-associated macrophages, favoring the M1 immune-supportive phenotype over the M2 immunosuppressive phenotype. Collectively, our findings provide evidence that ketotifen-induced TME reprogramming can improve the efficacy of nanomedicine-based chemo-immunotherapy in sarcomas.
AbstractList Sarcomas are a heterogeneous group of rare cancers that originate in soft tissues or bones. Their complexity and tendency for metastases make treatment challenging, highlighting the need for new therapeutic approaches to improve patient survival. The difficulties in treating these cancers primarily stem from abnormalities within the tumor microenvironment (TME), which leads to reduced blood flow and oxygen levels in tumors. Consequently, this hampers the effective delivery of drugs to tumors and diminishes treatment efficacy despite higher toxic doses of chemotherapy. In this study, we tested the mechanotherapeutic ketotifen combined with either pegylated liposomal doxorubicin (PLD) or pegylated liposomal coencapsulated alendronate-doxorubicin (PLAD) plus anti-programmed cell death protein 1 antibody in mouse models of fibrosarcoma and osteosarcoma. We found that ketotifen successfully reprogrammed the TME by reducing tumor stiffness and increasing perfusion, proven by changes measured by shear-wave elastography and contrast-enhanced ultrasound, respectively, and enhanced the therapeutic efficacy of our nanomedicine-based chemo-immunotherapy protocols. Furthermore, we observed a trend toward improved antitumor responses when nano-chemotherapy is given alongside anti-programmed cell death protein 1 and when the immunomodulator alendronate was present in the treatment. We next investigated the mechanisms of action of this combination. Ketotifen combined with nanomedicine-based chemo-immunotherapy increased T-cell infiltration, specifically cytotoxic CD8+ T cells and CD4+ T helper cells, and decreased the number of regulatory T cells. In addition, the combination also altered the polarization of tumor-associated macrophages, favoring the M1 immune-supportive phenotype over the M2 immunosuppressive phenotype. Collectively, our findings provide evidence that ketotifen-induced TME reprogramming can improve the efficacy of nanomedicine-based chemo-immunotherapy in sarcomas.
Sarcomas are a heterogeneous group of rare cancers that originate in soft tissues or bones. Their complexity and tendency for metastases make treatment challenging, highlighting the need for new therapeutic approaches to improve patient survival. The difficulties in treating these cancers primarily stem from abnormalities within the tumor microenvironment (TME), which leads to reduced blood flow and oxygen levels in tumors. Consequently, this hampers the effective delivery of drugs to tumors and diminishes treatment efficacy despite higher toxic doses of chemotherapy. In this study, we tested the mechanotherapeutic ketotifen combined with either pegylated liposomal doxorubicin (PLD) or pegylated liposomal coencapsulated alendronate-doxorubicin (PLAD) plus anti-programmed cell death protein 1 antibody in mouse models of fibrosarcoma and osteosarcoma. We found that ketotifen successfully reprogrammed the TME by reducing tumor stiffness and increasing perfusion, proven by changes measured by shear-wave elastography and contrast-enhanced ultrasound, respectively, and enhanced the therapeutic efficacy of our nanomedicine-based chemo-immunotherapy protocols. Furthermore, we observed a trend toward improved antitumor responses when nano-chemotherapy is given alongside anti-programmed cell death protein 1 and when the immunomodulator alendronate was present in the treatment. We next investigated the mechanisms of action of this combination. Ketotifen combined with nanomedicine-based chemo-immunotherapy increased T-cell infiltration, specifically cytotoxic CD8+ T cells and CD4+ T helper cells, and decreased the number of regulatory T cells. In addition, the combination also altered the polarization of tumor-associated macrophages, favoring the M1 immune-supportive phenotype over the M2 immunosuppressive phenotype. Collectively, our findings provide evidence that ketotifen-induced TME reprogramming can improve the efficacy of nanomedicine-based chemo-immunotherapy in sarcomas.Sarcomas are a heterogeneous group of rare cancers that originate in soft tissues or bones. Their complexity and tendency for metastases make treatment challenging, highlighting the need for new therapeutic approaches to improve patient survival. The difficulties in treating these cancers primarily stem from abnormalities within the tumor microenvironment (TME), which leads to reduced blood flow and oxygen levels in tumors. Consequently, this hampers the effective delivery of drugs to tumors and diminishes treatment efficacy despite higher toxic doses of chemotherapy. In this study, we tested the mechanotherapeutic ketotifen combined with either pegylated liposomal doxorubicin (PLD) or pegylated liposomal coencapsulated alendronate-doxorubicin (PLAD) plus anti-programmed cell death protein 1 antibody in mouse models of fibrosarcoma and osteosarcoma. We found that ketotifen successfully reprogrammed the TME by reducing tumor stiffness and increasing perfusion, proven by changes measured by shear-wave elastography and contrast-enhanced ultrasound, respectively, and enhanced the therapeutic efficacy of our nanomedicine-based chemo-immunotherapy protocols. Furthermore, we observed a trend toward improved antitumor responses when nano-chemotherapy is given alongside anti-programmed cell death protein 1 and when the immunomodulator alendronate was present in the treatment. We next investigated the mechanisms of action of this combination. Ketotifen combined with nanomedicine-based chemo-immunotherapy increased T-cell infiltration, specifically cytotoxic CD8+ T cells and CD4+ T helper cells, and decreased the number of regulatory T cells. In addition, the combination also altered the polarization of tumor-associated macrophages, favoring the M1 immune-supportive phenotype over the M2 immunosuppressive phenotype. Collectively, our findings provide evidence that ketotifen-induced TME reprogramming can improve the efficacy of nanomedicine-based chemo-immunotherapy in sarcomas.
Author Charalambous, Antonia
Michael, Christina
Gabizon, Alberto A
Stylianopoulos, Triantafyllos
Voutouri, Chrysovalantis
Mpekris, Fotios
Panagi, Myrofora
Author_xml – sequence: 1
  givenname: Antonia
  orcidid: 0000-0001-5895-3697
  surname: Charalambous
  fullname: Charalambous, Antonia
  organization: Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus
– sequence: 2
  givenname: Fotios
  orcidid: 0000-0002-7125-4062
  surname: Mpekris
  fullname: Mpekris, Fotios
  organization: Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus
– sequence: 3
  givenname: Myrofora
  orcidid: 0000-0002-6256-3250
  surname: Panagi
  fullname: Panagi, Myrofora
  organization: Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus
– sequence: 4
  givenname: Chrysovalantis
  orcidid: 0000-0003-3172-9489
  surname: Voutouri
  fullname: Voutouri, Chrysovalantis
  organization: Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus
– sequence: 5
  givenname: Christina
  orcidid: 0000-0003-1081-6807
  surname: Michael
  fullname: Michael, Christina
  organization: Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus
– sequence: 6
  givenname: Alberto A
  orcidid: 0000-0003-1332-1164
  surname: Gabizon
  fullname: Gabizon, Alberto A
  organization: Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
– sequence: 7
  givenname: Triantafyllos
  orcidid: 0000-0002-3093-1696
  surname: Stylianopoulos
  fullname: Stylianopoulos, Triantafyllos
  organization: Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38940284$$D View this record in MEDLINE/PubMed
BookMark eNo9kMlOwzAQhi1URBd4BFCOXAxem-QIFUslFgnK2bj2pA2q7WI3SH17XAocRrPon-0bop4PHhA6peSCUlldUsklLumYXzxOZphxTMqSHaBBrle4klT0fuK9po-GKX0QQqua0SPU51UtCKvEAL3POhdi8diaGMB_tTF4B35TvMA6hkXUzrV-UUxdzr4gFU_aBwe2Na0HfK0T2GKyBBfw1LnOh80Sol5vi9YXrzqa4HQ6RoeNXiU4-fUj9HZ7M5vc44fnu-nk6gEbWpUb3BhDQAtpYZ4PyzaujZlzJjSvmLRc20Y3tp6DZlSK2tqGWMlrK8alECXhfITO93PzpZ8dpI1ybTKwWmkPoUuKk5IzLgWps1TupfnnlCI0ah1bp-NWUaJ2cNUOnNqBUxmuYlzt4Oa-s98V3TxD-O_6o8m_AUE4eXs
Cites_doi 10.1158/0008-5472.CAN-12-4521
10.1016/j.bpj.2010.06.016
10.1016/j.jconrel.2022.12.016
10.1016/j.intimp.2022.109030
10.12659/MSM.907293
10.1186/s12885-020-07199-0
10.1038/s41591-019-0432-4
10.1038/ncomms3516
10.1016/j.annonc.2021.07.006
10.1073/pnas.1018892108
10.1016/j.jconrel.2022.03.008
10.3389/fonc.2022.1069963
10.1073/pnas.1819889116
10.1016/j.annonc.2021.08.1995
10.1158/1078-0432.CCR-24-0246
10.1016/S1470-2045(17)30624-1
10.1007/s00011-011-0409-3
10.1146/annurev-bioeng-071813-105259
10.1002/adtp.202000289
10.1080/10837450.2016.1265553
10.1016/j.actbio.2023.06.007
10.1002/cam4.1518
10.1186/1479-5876-9-177
10.1016/j.msec.2019.110533
10.7150/ntno.75045
10.1038/s41467-022-34744-1
10.1080/1061186X.2016.1191081
10.1038/nrclinonc.2010.139
10.1016/j.semcancer.2019.12.001
10.1001/jama.2020.1707
10.1001/jamaoncol.2019.0892
10.1158/0008-5472.CAN-05-2242
10.1038/s41571-021-00519-8
10.1016/j.addr.2020.05.012
10.1073/pnas.1213353109
10.18632/oncotarget.20136
10.1016/j.jconrel.2017.12.023
10.7150/thno.36936
10.3390/biom13091309
10.1002/cti2.1080
10.1038/srep46140
10.3389/fimmu.2022.938439
10.1038/s41571-019-0308-z
ContentType Journal Article
Copyright 2024 American Association for Cancer Research.
Copyright_xml – notice: 2024 American Association for Cancer Research.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1158/1535-7163.MCT-23-0772
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1538-8514
EndPage 1567
ExternalDocumentID 10_1158_1535_7163_MCT_23_0772
38940284
Genre Journal Article
GrantInformation_xml – fundername: HORIZON EUROPE European Research Council (ERC)
  grantid: 863955
GroupedDBID ---
123
18M
2FS
2WC
34G
39C
53G
5RE
AAJMC
ABOCM
ACGFO
ACIWK
ACPRK
ADBBV
AENEX
AFHIN
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BR6
BTFSW
CGR
CS3
CUY
CVF
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
GX1
IH2
KQ8
L7B
NPM
OK1
P2P
QTD
RCR
RHF
RHI
TR2
WOQ
YBU
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c187t-fcc0ea45deb028b0269ccb324a3825d3adfafd9bea21549ddf0d539d467447033
ISSN 1535-7163
1538-8514
IngestDate Mon Nov 04 17:17:44 EST 2024
Fri Nov 22 01:29:23 EST 2024
Thu Nov 28 21:26:15 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
License 2024 American Association for Cancer Research.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c187t-fcc0ea45deb028b0269ccb324a3825d3adfafd9bea21549ddf0d539d467447033
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-1332-1164
0000-0002-6256-3250
0000-0003-3172-9489
0000-0003-1081-6807
0000-0002-3093-1696
0000-0001-5895-3697
0000-0002-7125-4062
PMID 38940284
PQID 3073235409
PQPubID 23479
PageCount 13
ParticipantIDs proquest_miscellaneous_3073235409
crossref_primary_10_1158_1535_7163_MCT_23_0772
pubmed_primary_38940284
PublicationCentury 2000
PublicationDate 2024-Nov-04
2024-11-04
20241104
PublicationDateYYYYMMDD 2024-11-04
PublicationDate_xml – month: 11
  year: 2024
  text: 2024-Nov-04
  day: 04
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular cancer therapeutics
PublicationTitleAlternate Mol Cancer Ther
PublicationYear 2024
References Raverdeau (2024110408140659300_bib45) 2019; 8
Chauhan (2024110408140659300_bib25) 2013; 4
Wu (2024110408140659300_bib4) 2015; 10
Pilavaki (2024110408140659300_bib10) 2023; 12
Jain (2024110408140659300_bib18) 2010; 7
Gronchi (2024110408140659300_bib1) 2021; 32
Rogers (2024110408140659300_bib43) 2011; 9
Voorwerk (2024110408140659300_bib39) 2019; 25
La-Beck (2024110408140659300_bib32) 2021; 68
Augsburger (2024110408140659300_bib41) 2017; 8
Matsumura (2024110408140659300_bib9) 1986; 46
Islam (2024110408140659300_bib31) 2022; 6
Dhupkar (2024110408140659300_bib38) 2018; 7
Martin (2024110408140659300_bib11) 2020; 17
Panagi (2024110408140659300_bib28) 2024; 30
Tian (2024110408140659300_bib6) 2020; 20
Panagi (2024110408140659300_bib20) 2022; 13
Gill (2024110408140659300_bib42) 2021; 18
Mpekris (2024110408140659300_bib19) 2022; 345
Panagi (2024110408140659300_bib40) 2020; 10
Strauss (2024110408140659300_bib2) 2021; 32
Jain (2024110408140659300_bib15) 2014; 16
Tap (2024110408140659300_bib3) 2020; 323
Stylianopoulos (2024110408140659300_bib12) 2010; 99
Murphy (2024110408140659300_bib27) 2019; 5
Chauhan (2024110408140659300_bib26) 2019; 166
Diop-Frimpong (2024110408140659300_bib16) 2011; 108
Monument (2024110408140659300_bib29) 2012; 61
Stylianopoulos (2024110408140659300_bib14) 2012; 109
Xia (2024110408140659300_bib23) 2018; 23
Zhao (2024110408140659300_bib24) 2022; 13
Gabizon (2024110408140659300_bib8) 2020; 158
Shmeeda (2024110408140659300_bib30) 2016; 24
Stylianopoulos (2024110408140659300_bib13) 2013; 73
Voutouri (2024110408140659300_bib22) 2021; 4
Tawbi (2024110408140659300_bib7) 2017; 18
Mpekris (2024110408140659300_bib34) 2023; 353
Rajan (2024110408140659300_bib37) 2018; 271
Xin (2024110408140659300_bib35) 2017; 23
Nourmohammadi (2024110408140659300_bib5) 2020; 109
Voutouri (2024110408140659300_bib36) 2023; 167
Islam (2024110408140659300_bib44) 2023; 13
Papageorgis (2024110408140659300_bib21) 2017; 7
Zheng (2024110408140659300_bib33) 2022; 110
McKee (2024110408140659300_bib17) 2006; 66
References_xml – volume: 73
  start-page: 3833
  year: 2013
  ident: 2024110408140659300_bib13
  article-title: Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-4521
  contributor:
    fullname: Stylianopoulos
– volume: 10
  start-page: 5219
  year: 2015
  ident: 2024110408140659300_bib4
  article-title: D-α-tocopherol polyethylene glycol succinate-based derivative nanoparticles as a novel carrier for paclitaxel delivery
  publication-title: Int J Nanomedicine
  contributor:
    fullname: Wu
– volume: 99
  start-page: 1342
  year: 2010
  ident: 2024110408140659300_bib12
  article-title: Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions
  publication-title: Biophys J
  doi: 10.1016/j.bpj.2010.06.016
  contributor:
    fullname: Stylianopoulos
– volume: 353
  start-page: 956
  year: 2023
  ident: 2024110408140659300_bib34
  article-title: Translational nanomedicine potentiates immunotherapy in sarcoma by normalizing the microenvironment
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2022.12.016
  contributor:
    fullname: Mpekris
– volume: 110
  start-page: 109030
  year: 2022
  ident: 2024110408140659300_bib33
  article-title: Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2022.109030
  contributor:
    fullname: Zheng
– volume: 23
  start-page: 5430
  year: 2017
  ident: 2024110408140659300_bib35
  article-title: Parameters for contrast-enhanced ultrasound (CEUS) of enlarged superficial lymph nodes for the evaluation of therapeutic response in lymphoma: a preliminary study
  publication-title: Med Sci Monit
  doi: 10.12659/MSM.907293
  contributor:
    fullname: Xin
– volume: 20
  start-page: 698
  year: 2020
  ident: 2024110408140659300_bib6
  article-title: Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
  publication-title: BMC Cancer
  doi: 10.1186/s12885-020-07199-0
  contributor:
    fullname: Tian
– volume: 25
  start-page: 920
  year: 2019
  ident: 2024110408140659300_bib39
  article-title: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
  publication-title: Nat Med
  doi: 10.1038/s41591-019-0432-4
  contributor:
    fullname: Voorwerk
– volume: 4
  start-page: 2516
  year: 2013
  ident: 2024110408140659300_bib25
  article-title: Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
  publication-title: Nat Commun
  doi: 10.1038/ncomms3516
  contributor:
    fullname: Chauhan
– volume: 32
  start-page: 1348
  year: 2021
  ident: 2024110408140659300_bib1
  article-title: Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2021.07.006
  contributor:
    fullname: Gronchi
– volume: 108
  start-page: 2909
  year: 2011
  ident: 2024110408140659300_bib16
  article-title: Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1018892108
  contributor:
    fullname: Diop-Frimpong
– volume: 345
  start-page: 190
  year: 2022
  ident: 2024110408140659300_bib19
  article-title: Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2022.03.008
  contributor:
    fullname: Mpekris
– volume: 12
  start-page: 1069963
  year: 2023
  ident: 2024110408140659300_bib10
  article-title: Exploring the landscape of immunotherapy approaches in sarcomas
  publication-title: Front Oncol
  doi: 10.3389/fonc.2022.1069963
  contributor:
    fullname: Pilavaki
– volume: 166
  start-page: 10674
  year: 2019
  ident: 2024110408140659300_bib26
  article-title: Reprogramming the microenvironment with tumorselective angiotensin blockers enhances cancer immunotherapy
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1819889116
  contributor:
    fullname: Chauhan
– volume: 32
  start-page: 1520
  year: 2021
  ident: 2024110408140659300_bib2
  article-title: Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up☆
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2021.08.1995
  contributor:
    fullname: Strauss
– volume: 30
  start-page: 2582
  issue: 11
  year: 2024
  ident: 2024110408140659300_bib28
  article-title: Stabilizing tumor-resident mast cells restores T-cell infiltration and sensitizes sarcomas to PD-L1 inhibition
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-24-0246
  contributor:
    fullname: Panagi
– volume: 18
  start-page: 1493
  year: 2017
  ident: 2024110408140659300_bib7
  article-title: Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30624-1
  contributor:
    fullname: Tawbi
– volume: 61
  start-page: 285
  year: 2012
  ident: 2024110408140659300_bib29
  article-title: The mast cell stabilizer ketotifen reduces joint capsule fibrosis in a rabbit model of post-traumatic joint contractures
  publication-title: Inflamm Res
  doi: 10.1007/s00011-011-0409-3
  contributor:
    fullname: Monument
– volume: 16
  start-page: 321
  year: 2014
  ident: 2024110408140659300_bib15
  article-title: The role of mechanical forces in tumor growth and therapy
  publication-title: Annu Rev Biomed Eng
  doi: 10.1146/annurev-bioeng-071813-105259
  contributor:
    fullname: Jain
– volume: 4
  start-page: 2000289
  year: 2021
  ident: 2024110408140659300_bib22
  article-title: Endothelin inhibition potentiates cancer immunotherapy revealing mechanical biomarkers predictive of response
  publication-title: Adv Ther
  doi: 10.1002/adtp.202000289
  contributor:
    fullname: Voutouri
– volume: 23
  start-page: 13
  year: 2018
  ident: 2024110408140659300_bib23
  article-title: Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer
  publication-title: Pharm Dev Technol
  doi: 10.1080/10837450.2016.1265553
  contributor:
    fullname: Xia
– volume: 167
  start-page: 121
  year: 2023
  ident: 2024110408140659300_bib36
  article-title: Ultrasound stiffness and perfusion markers correlate with tumor volume responses to immunotherapy
  publication-title: Acta Biomater
  doi: 10.1016/j.actbio.2023.06.007
  contributor:
    fullname: Voutouri
– volume: 7
  start-page: 2654
  year: 2018
  ident: 2024110408140659300_bib38
  article-title: Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases
  publication-title: Cancer Med
  doi: 10.1002/cam4.1518
  contributor:
    fullname: Dhupkar
– volume: 9
  start-page: 177
  year: 2011
  ident: 2024110408140659300_bib43
  article-title: Tumour macrophages as potential targets of bisphosphonates
  publication-title: J Transl Med
  doi: 10.1186/1479-5876-9-177
  contributor:
    fullname: Rogers
– volume: 109
  start-page: 11053
  year: 2020
  ident: 2024110408140659300_bib5
  article-title: Cerium oxide nanoparticles: a promising tool for the treatment of fibrosarcoma in-vivo
  publication-title: Mater Sci Eng C Mater Biol Appl
  doi: 10.1016/j.msec.2019.110533
  contributor:
    fullname: Nourmohammadi
– volume: 6
  start-page: 451
  year: 2022
  ident: 2024110408140659300_bib31
  article-title: Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model
  publication-title: Nanotheranostics
  doi: 10.7150/ntno.75045
  contributor:
    fullname: Islam
– volume: 13
  start-page: 7165
  year: 2022
  ident: 2024110408140659300_bib20
  article-title: Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models
  publication-title: Nat Commun
  doi: 10.1038/s41467-022-34744-1
  contributor:
    fullname: Panagi
– volume: 24
  start-page: 878
  year: 2016
  ident: 2024110408140659300_bib30
  article-title: Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer
  publication-title: J Drug Target
  doi: 10.1080/1061186X.2016.1191081
  contributor:
    fullname: Shmeeda
– volume: 7
  start-page: 653
  year: 2010
  ident: 2024110408140659300_bib18
  article-title: Delivering nanomedicine to solid tumors
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2010.139
  contributor:
    fullname: Jain
– volume: 68
  start-page: 175
  year: 2021
  ident: 2024110408140659300_bib32
  article-title: Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2019.12.001
  contributor:
    fullname: La-Beck
– volume: 46
  start-page: 6387
  year: 1986
  ident: 2024110408140659300_bib9
  article-title: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs
  publication-title: Cancer Res
  contributor:
    fullname: Matsumura
– volume: 323
  start-page: 1266
  year: 2020
  ident: 2024110408140659300_bib3
  article-title: Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial
  publication-title: JAMA
  doi: 10.1001/jama.2020.1707
  contributor:
    fullname: Tap
– volume: 5
  start-page: 1020
  year: 2019
  ident: 2024110408140659300_bib27
  article-title: Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2019.0892
  contributor:
    fullname: Murphy
– volume: 66
  start-page: 2509
  year: 2006
  ident: 2024110408140659300_bib17
  article-title: Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-2242
  contributor:
    fullname: McKee
– volume: 18
  start-page: 609
  year: 2021
  ident: 2024110408140659300_bib42
  article-title: Advancing therapy for osteosarcoma
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-021-00519-8
  contributor:
    fullname: Gill
– volume: 158
  start-page: 140
  year: 2020
  ident: 2024110408140659300_bib8
  article-title: Translational considerations in nanomedicine: the oncology perspective
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2020.05.012
  contributor:
    fullname: Gabizon
– volume: 109
  start-page: 15101
  year: 2012
  ident: 2024110408140659300_bib14
  article-title: Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1213353109
  contributor:
    fullname: Stylianopoulos
– volume: 8
  start-page: 104638
  year: 2017
  ident: 2024110408140659300_bib41
  article-title: Current diagnostics and treatment of fibrosarcoma-perspectives for future therapeutic targets and strategies
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.20136
  contributor:
    fullname: Augsburger
– volume: 271
  start-page: 139
  year: 2018
  ident: 2024110408140659300_bib37
  article-title: Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2017.12.023
  contributor:
    fullname: Rajan
– volume: 10
  start-page: 1910
  year: 2020
  ident: 2024110408140659300_bib40
  article-title: TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity
  publication-title: Theranostics
  doi: 10.7150/thno.36936
  contributor:
    fullname: Panagi
– volume: 13
  start-page: 1309
  year: 2023
  ident: 2024110408140659300_bib44
  article-title: Pegylated liposomal alendronate biodistribution, immune modulation, and tumor growth inhibition in a murine melanoma model
  publication-title: Biomolecules
  doi: 10.3390/biom13091309
  contributor:
    fullname: Islam
– volume: 8
  start-page: e01080
  year: 2019
  ident: 2024110408140659300_bib45
  article-title: γδ T cells in cancer: a small population of lymphocytes with big implications
  publication-title: Clin Transl Immunology
  doi: 10.1002/cti2.1080
  contributor:
    fullname: Raverdeau
– volume: 7
  start-page: 46140
  year: 2017
  ident: 2024110408140659300_bib21
  article-title: Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo- and nanotherapeutics in a size-independent manner
  publication-title: Sci Rep
  doi: 10.1038/srep46140
  contributor:
    fullname: Papageorgis
– volume: 13
  start-page: 938439
  year: 2022
  ident: 2024110408140659300_bib24
  article-title: Enhanced therapeutic efficacy of combining losartan and chemo-immunotherapy for triple negative breast cancer
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.938439
  contributor:
    fullname: Zhao
– volume: 17
  start-page: 251
  year: 2020
  ident: 2024110408140659300_bib11
  article-title: Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-019-0308-z
  contributor:
    fullname: Martin
SSID ssj0018921
Score 2.4981508
Snippet Sarcomas are a heterogeneous group of rare cancers that originate in soft tissues or bones. Their complexity and tendency for metastases make treatment...
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
StartPage 1555
SubjectTerms Animals
Cell Line, Tumor
Doxorubicin - administration & dosage
Doxorubicin - analogs & derivatives
Doxorubicin - pharmacology
Doxorubicin - therapeutic use
Female
Humans
Immunotherapy - methods
Mice
Nanomedicine - methods
Polyethylene Glycols - chemistry
Sarcoma - drug therapy
Sarcoma - pathology
Sarcoma - therapy
Tumor Microenvironment - drug effects
Title Tumor Microenvironment Reprogramming Improves Nanomedicine-Based Chemo-Immunotherapy in Sarcomas
URI https://www.ncbi.nlm.nih.gov/pubmed/38940284
https://www.proquest.com/docview/3073235409
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAvE-PawVCQeEMuqWOn8SNMTANUBKJDezNO7EgTWjKlCdL4Y_w9znESNxkFMR4aVZFynPp8PRefGyHPtY7iTC8kBWPVUh4llkrN5tTEMbMcVLw2LkH2Q3x8wt-ditPJ5Ocga6mp01n2Y2tdyf9wFe4BX7FK9hqc9UThBnwH_sIVOAzXf-Nxc15WmPlelYOCNTSq26yrc5cO4I4N7BoFadmH0ulr0F7mBbYLKOlbrBHpKrFcGeBnQL_PG-rHPfVzdDFPLLMuN7Gv3PJ2OQbvNWAsLZt115oAZIaX_MsL-61qmxoc4fQg_9xHNy3JHc5egmIoK__Il7KpMU7QNUK4XJffMRmzPhudVzDuCvf4SMQKCl5aK9bsRuwCMPhQLrd1yD3-5gMpCzaQGGhscEEX27WBwAoHv-BsebiiLKLhop0WNO6-fUUr-lxF5yWJRCEZhWQUkFEsUkjmBrmJHRhxaMP7T5vwVSJZ16i3XbkrHQMyL7e-zdgo-oOn4yye1R2y27kqwasWd3tkYou75NayQ9A98tXBL7gKv2AEv6CHX_A7_IIt8AvOiqCH331ycvRmdXhMu4EdNJsni5rmWRZazYWxKZit8IlllqVgsusoYcJE2uQ6NzK1IA0El8bkoRGRNDjxhoPqiR6QnaIs7CMSSC0kY3moeRxyjkMERGbj3IB3b2NhkimZ9TumLtq-LOqvnJqSZ_2-KpCgGBbThYV_g0Itx_D4U07Jw3bDPUkw5zn8FL5_3eUek9sb8D8hO3XV2AMwX-v0qYPKL7YBmjs
link.rule.ids 314,780,784,27924,27925
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tumor+Microenvironment+Reprogramming+Improves+Nanomedicine-Based+Chemo-Immunotherapy+in+Sarcomas&rft.jtitle=Molecular+cancer+therapeutics&rft.au=Charalambous%2C+Antonia&rft.au=Mpekris%2C+Fotios&rft.au=Panagi%2C+Myrofora&rft.au=Voutouri%2C+Chrysovalantis&rft.date=2024-11-04&rft.issn=1535-7163&rft.eissn=1538-8514&rft.volume=23&rft.issue=11&rft.spage=1555&rft.epage=1567&rft_id=info:doi/10.1158%2F1535-7163.MCT-23-0772&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_1535_7163_MCT_23_0772
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1535-7163&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1535-7163&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1535-7163&client=summon